Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Charlée NardinAymeric HennemannKadiatou DialloElisa Funck-BrentanoEve PuzenatValentine HeidelbergerGéraldine JeudyMahtab SamimiCandice LesageLise BoussemartLucie PeuvrelJacques RouanetFlorence Brunet-PossentiEmilie GerardAlice SerisThomas JouaryMélanie Saint-JeanMarc PuyraveauPhilippe SaiagFrançois AubinPublished in: Cancers (2023)
Rechallenging advanced melanoma patients with ICI after previous disease control induced by these inhibitors resulted in high response rates (54%) and disease control (75%). Therefore, ICI rechallenge should be considered as a relevant therapeutic option.